Pawlicki M, Jońca M, Krzemieniecki K, Zuchowska-Vogelgesang B
Kliniki Chemioterapii Instytutu Onkologii w Krakowie.
Wiad Lek. 1993 Dec;46(23-24):912-4.
During 10 years patients with malignant melanoma were followed up after radical removal of primary tumour and metastatic regional lymph nodes, the half of whom was given immunomodulation with the preparation Poly-A Poly-U in a controlled clinical trial. It was found that the performed immunomodulation exerted slight effect on the course of malignant melanoma causing later development of recurrence, less dynamic course of the disease, longer asymptomatic periods in relation to the control group. No effect of the drug administration was observed on longterm survival.
在10年期间，对原发性肿瘤和转移性区域淋巴结进行根治性切除后的恶性黑色素瘤患者进行了随访，其中一半患者在一项对照临床试验中接受了聚肌胞苷酸（Poly-A Poly-U）制剂的免疫调节治疗。结果发现，所进行的免疫调节对恶性黑色素瘤的病程产生了轻微影响，导致复发较晚出现、疾病进展较缓慢、与对照组相比无症状期更长。未观察到给药对长期生存有影响。
